Developing antagonists for the Met-HGF/SF protein-protein interaction using a fragment-based approach

Molecular Cancer Therapeutics

Volumn 15, Issue 1, 2016, Pages 3-14

  Winter, Anja ^a,d   Sigurdardottir, Anna G ^a,e   DiCara, Danielle ^a,b,g   Valenti, Giovanni ^c   Blundell, Tom L ^a   Gherardi, Ermanno ^b,f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^f UNIVERSITY OF PAVIA   (Italy)

^g GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; MOLECULAR LIBRARY; PROTEIN BINDING; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR;

ALPHA CHAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; FEMALE; MOLECULAR DOCKING; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; ANIMAL; CELL LINE; CHEMISTRY; CONFORMATION; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; MOLECULAR LIBRARY; MOLECULAR MODEL; PHOSPHORYLATION; PROCEDURES; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84958159452     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0446     Document Type: Article

References (51)

1. Cooper CS, Blair DG, OskarssonMK, Tainsky MA, Eader LA, Vande Woude GF. Characterization of human transforming genes from chemically transformed, teratocarcinoma, and pancreatic carcinoma cell lines. Cancer Res 1984;44:1-10.
2. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A 1987;84: 6379-83.
3. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4
4. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3.
5. Zarnegar R, Michalopoulos G. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res 1989;49:3314-20.
6. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblastderived modulator of epithelial cell mobility. Nature 1987;327:239-42.
7. Gherardi E, Gray J, Stoker M, Perryman M, Furlong R. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc Natl Acad Sci U S A 1989;89:5844-8.
8. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373:699-702.
9. Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/ scatter factor. Nature 1995;373:702-5.
10. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration ofmyogenic precursor cells into the limb bud. Nature 1995;376:768-71.
11. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
12. Lee YH, Apolo AB, Agarwal PK, Bottaro DP. Characterization of HGF/Met signaling in cell lines derived from urothelial carcinoma of the bladder. Cancers 2014;6:2313-29.
13. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386-96.
14. Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/ HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996;87:1063-9.
15. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670-9.
16. Mahadevan D, Theiss N, Morales C, Stejskal AE, Cooke LS, Zhu M, et al. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST). Oncotarget 2015;6: 1954-66.
17. Jung KA, Choi BH, Kwak MK. The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression. Mol Pharmacol 2015;87:465-76.
18. Ozasa H, Oguri T, Maeno K, Takakuwa O, Kunii E, Yagi Y, et al. Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells. Cancer Sci 2014;105:1032-9.
19. Jubb H, Blundell TL, Ascher DB. Flexibility and small pockets at protein-protein interfaces: new insights into druggability. Prog Biophys Mol Biol 2015;119:2-9.
20. Fuller JC, Burgoyne NJ, Jackson RM. Predicting druggable binding sites at the protein-protein interface. Drug Discov Today 2009;14:155-61.
21. Winter A, Higueruelo AP, Marsh M, Sigurdardottir A, Pitt WR, Blundell TL. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Q Rev Biophys 2012;45:383-426.
22. Yang RY, Yang KS, Pike LJ, Marshall GR. Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors. Chem Biol Drug Des 2010;76:1-9.
23. Scott DE, Coyne AG, Venkitaraman A, Blundell TL, Abell C, Hyvonen M. Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases. ChemMedChem 2015;10:296-303.
24. Muratore G, Goracci L, Mercorelli B, Foeglein A, Digard P, CrucianiG, et al. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc Natl Acad Sci U S A 2012;109:6247-52.
25. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D, et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010;6:442-8.
26. Donate LE, Gherardi E, Srinivasan N, Sowdhamini R, Aparicio S, Blundell TL. Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci 1994;3:2378-94.
27. HolmesO, Pillozzi S, Deakin JA,Carafoli F, Kemp L, Butler PJ, et al. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. J Mol Biol 2007;367:395-408.
28. Lokker NA, Mark MR, Luis EA, Bennett GL, Robbins KA, Baker JB, et al. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J 1992;11:2503-10.
29. Blaszczyk M, Harmer NJ, Chirgadze DY, Ascher DB, Blundell TL. Achieving high signal-to-noise in cell regulatory systems: Spatial organization of multiprotein transmembrane assemblies of FGFR and MET receptors. Progress in Biophysics and Molecular Biology 2015;118:103-11.
30. Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J 2004;23:2325-35.
31. Oelmann S, Stanley P, Gerardy-Schahn R. Point mutations identified in Lec8 Chinese hamster ovary glycosylationmutants that inactivate both the UDP-galactose and CMP-sialic acid transporters. J Biol Chem 2001;276: 26291-300.
32. Chirgadze DY, Hepple JP, Zhou H, Byrd RA, Blundell TL, Gherardi E. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimeriztion and receptor binding. Nat Struct Biol 1999;6: 72-9.
33. Irwin JJ, Shoichet BK. ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005;45:177-82.
34. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
35. Teague SJ, Davis AM, Leeson PD, Oprea T. The design of leadlike combinatorial libraries. Angew Chem Int Ed Engl 1999;38:3743-8.
36. Wear MA, Patterson A, Malone K, Dunsmore C, Turner NJ, Walkinshaw MD. A surface plasmon resonance-based assay for small molecule inhibitors of human cyclophilin A. Anal Biochem 2005;345:214-26.
37. Ferraris DM, Gherardi E, Di Y, Heinz DW, Niemann HH. Ligand-mediated dimerization of the Met receptor tyrosine kinase by the bacterial invasion protein InlB. J Mol Biol 2009;395:522-32.
38. Holland JD, Gyorffy B, Vogel R, Eckert K, Valenti G, Fang L, et al. Combined Wnt/beta-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. Cell Rep 2013;5:1214-27.
39. Sigurdardottir AG, Winter A, Sobkowicz A, Fragai M, Chirgadze D, Ascher DB, et al. Exploring the chemical space of the lysine-binding pocket of the first kringle domain of hepatocyte growth factor/scatter factor (HGF/SF) yields a new class of inhibitors of HGF/SF-MET binding. Chem Sci 2015;6:6147-57.
40. Niemann HH, Jager V, Butler PJ, van den Heuvel J, Schmidt S, Ferraris D, et al. Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB. Cell 2007;130:235-46.
41. Garner AL, Janda KD. Protein-protein interactions and cancer: targeting the central dogma. Curr Top Med Chem 2011;11:258-80.
42. Baker M. Fragment-based lead discovery grows up. Nat Rev Drug Discov 2013;12:5-7.
43. Blazer LL, Neubig RR. Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. Neuropsychopharmacology 2009;34:126-41.
44. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999;103:931-43.
45. Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW. Oncogenic protein interfaces: small molecules, big challenges. Nat Rev Cancer 2014;14: 248-62.
46. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993-6.
47. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450:1001-9.
48. Lund G, Dudkin S, Borkin D, Ni W, Grembecka J, Cierpicki T. Inhibition of CDC25B phosphatase through disruption of protein-protein interaction. ACS Chem Biol 2015;10:390-4.
49. Douse CH, Vrielink N, Wenlin Z, Cota E, Tate EW. Targeting a dynamic protein-protein interaction: fragment screening against the malaria myosin A motor complex. ChemMedChem 2015;10:134-43.
50. Neumann T, Junker HD, Schmidt K, Sekul R. SPR-based fragment screening: advantages and applications. Curr Top Med Chem 2007;7: 1630-42.
51. Hubbard RE, Murray JB. Experiences in fragment-based lead discovery. Methods Enzymol 2011;493:509-31.